Search results
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Zacks· 2 days agoFree Report) were down 4.4% on May 10 after the company announced that the FDA has delayed the review timeline for its mRNA-based, respiratory syncytial virus (RSV) vaccine, mRNA-1345. Moderna ...
Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in Pfizer Stock | The Motley...
The Motley Fool· 2 days agoPfizer (PFE -0.21%) stock has struggled over the past year, losing around 28% of its value. Its...
Spotlight on Pfizer: Analyzing the Surge in Options Activity - Pfizer (NYSE:PFE)
Benzinga· 5 days agoAnalyzing Volume & Open Interest Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for < ...
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3...
Morningstar· 7 days agoFN Media Group News Commentary - There is much activity in finding better ways in mitigating muscle loss for the cancer patients… many clinical studies are looking for elite performance nutritional ...
FDA delays decision date for Moderna's RSV vaccine - Boston Business Journal
The Business Journals· 4 days agoJust days before its deadline, the U.S. Food and Drug Administration says it's giving itself more...